Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-07-15
    E.g., 2018-07-15

Articles

14318 items
2:37 PM, Jul 10, 2018  |  BC Innovations | Distillery Therapeutics

Infectious disease

INDICATION: Malaria Mouse studies suggest IL-33 or inhibiting NLRP3 could help treat cerebral malaria. In a mouse model of Plasmodium berghei-induced cerebral malaria treated with artesunate and chloroquine, brain levels of IL-33 were lower and brain...
2:37 PM, Jul 10, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Addiction Cell culture and mouse studies identified a peptide-based antagonist of the OPRD1/MOR heterodimer that could help treat opiate withdrawal. Chemical synthesis and testing in cell-based competitive binding and activity assays of conjugates linking OPRD1...
2:36 PM, Jul 10, 2018  |  BC Innovations | Distillery Therapeutics

Otologic

INDICATION: Hereditary deafness Patient samples and mouse studies suggest that inhibiting REST or HDAC could help treat hearing loss associated with gain-of-function REST mutations. In a family with inherited progressive hearing loss, sequencing of a...
2:36 PM, Jul 10, 2018  |  BC Innovations | Distillery Therapeutics

Infectious disease

INDICATION: Tuberculosis Cell culture and mouse studies identified an inhibitor of M. tuberculosis cytochrome bc1 that could help treat tuberculosis (TB). Screening of small molecule library in M. tuberculosis culture and chemical synthesis of analogs of...
2:36 PM, Jul 10, 2018  |  BC Innovations | Distillery Therapeutics

Dermatology

INDICATION: Blistering disorder Patient sample and cell culture studies suggest the generic antibiotic gentamicin could help treat Herlitz junctional epidermolysis bullosa, a blistering disorder caused by loss-of-function mutations in LAMB3. In patient-derived junctional epidermolysis cells and...
2:35 PM, Jul 10, 2018  |  BC Innovations | Distillery Therapeutics

Endocrine/Metabolic

INDICATION: Diabetes Mouse studies suggest inhibiting FST could help treat insulin resistance and glucose intolerance. In a genetic mouse model of glucose intolerance and hyper insulinemia, liver-specific knockdown of FST decreased hepatic glucose production, serum insulin...
2:35 PM, Jul 10, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Melanoma, colorectal cancer In vitro, cell culture and mouse studies identified an aminopyrimidine-based dual MAPK1/MAPK3 inhibitor that could help treat BRAF-mutant melanoma and colorectal cancer. Fragment-based screening, chemical synthesis and in vitro enzyme activity...
6:11 PM, Jun 28, 2018  |  BC Innovations | Tools & Techniques

QT replacement plan

FDA has completed validation of a preclinical assay system that could replace clinical QT testing, a move it hopes will lower development costs and reduce false alarms of arrhythmia risk. The question for drug developers...
5:43 PM, Jun 28, 2018  |  BC Innovations | Product R&D

Highly personal

Pact Pharma Inc. has raised $120 million in venture financing to tackle one of the most complex forms of personalized medicine proposed to date: neoantigen-targeted T cells. Backed by Alphabet Inc.’s GV, the company is...
3:51 PM, Jun 28, 2018  |  BC Innovations | Translation in Brief

Conformist nanobodies

A University of Zurich team in collaboration with Roche has figured out how to make fully synthetic nanobodies that can bind to membrane proteins in specific conformations -- simultaneously opening up new target space for...

Pages